Status:
COMPLETED
POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Hepatitis C, Chronic
Eligibility:
All Genders
18+ years
Brief Summary
This single arm study will investigate the predictive value of a week 4 virological response on sustained virological response in patients with chronic hepatitis C, genotype 2 or 3, treated with PEGAS...
Eligibility Criteria
Inclusion
- adult patients, \>=18 years of age;
- positive serum HCV RNA.
Exclusion
- co-infection with HIV or HBV (patients with a positive HBsAg);
- previous treatment with interferon, or peginterferon and/or ribavirin;
- severe hepatic dysfunction or decompensated cirrhosis of liver.
Key Trial Info
Start Date :
November 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
262 Patients enrolled
Trial Details
Trial ID
NCT00700401
Start Date
November 1 2008
End Date
November 1 2010
Last Update
June 21 2016
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Vitória, Espírito Santo, Brazil, 29043-260
2
Brasília, Federal District, Brazil, 70335900
3
São Luís, Maranhão, Brazil, 65020560
4
Rio de Janeiro, Rio de Janeiro, Brazil, 20020-022